Cabaletta Bio Inc (NASDAQ:CABA) — Market Cap & Net Worth
Market Cap & Net Worth: Cabaletta Bio Inc (CABA)
Cabaletta Bio Inc (NASDAQ:CABA) has a market capitalization of $463.08 Million ($463.08 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12828 globally and #3104 in its home market, demonstrating a -11.80% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cabaletta Bio Inc's stock price $2.84 by its total outstanding shares 163054796 (163.05 Million). Review Cabaletta Bio Inc (CABA) financial obligations to assess the company's total debt and financial obligations.
Cabaletta Bio Inc Market Cap History: 2019 to 2026
Cabaletta Bio Inc's market capitalization history from 2019 to 2026. Data shows change from $2.28 Billion to $463.08 Million (-17.25% CAGR).
Index Memberships
Cabaletta Bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.02% | #337 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1241 of 3165 |
Weight: Cabaletta Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cabaletta Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cabaletta Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
203492385408.00x
Cabaletta Bio Inc's market cap is 203492385408.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.03 Billion | $0.01 | -$32.49 Million | 203492385408.00x | N/A |
Competitor Companies of CABA by Market Capitalization
Companies near Cabaletta Bio Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Cabaletta Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Cabaletta Bio Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Cabaletta Bio Inc's market cap moved from $2.28 Billion to $ 463.08 Million, with a yearly change of -17.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $463.08 Million | +29.68% |
| 2025 | $357.09 Million | -3.52% |
| 2024 | $370.13 Million | -90.00% |
| 2023 | $3.70 Billion | +145.41% |
| 2022 | $1.51 Billion | +144.06% |
| 2021 | $617.98 Million | -69.63% |
| 2020 | $2.03 Billion | -10.67% |
| 2019 | $2.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Cabaletta Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $463.08 Million USD |
| MoneyControl | $463.08 Million USD |
| MarketWatch | $463.08 Million USD |
| marketcap.company | $463.08 Million USD |
| Reuters | $463.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase synd… Read more